Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07228338 · ClinicalTrials.gov registry record · Early Phase 1
Cholinergic Enhancement of Theta
A Early Phase 1 study, sponsored by University of Texas Southwestern Medical Center.
- Not yet
- Registry status
- Early Phase 1
- Development phase
- 50
- Enrollment target
NCT07228338 is a Early Phase 1 study that has not yet begun recruiting, run by University of Texas Southwestern Medical Center. The registered enrollment target is 50 participants.
The verdict
NCT07228338, a Early Phase 1 study, has not yet begun recruiting, sponsored by University of Texas Southwestern Medical Center.
- NOT YET RECRUITING
- Registry status
- Early Phase 1
- Development phase
- 50 participants
- Enrollment target
Study Summary
The goal of this study is to learn about the effects of Cobenfy KarXT (xanomeline and trospium chloride) on episodic memory processing, including specific effects on areas of the brain involved in memory and changes it may have on brain activity. The investigators will do this by testing epileptic patients who are already undergoing intracranial surgery for seizure monitoring, and measuring the activity from the brain areas being assessed. The main questions it aims to answer are 1) whether Cobenfy KarXT changes memory activity based on its agonist effect on muscarinic receptors and acetylcholine, and 2) what the nature of these brain activity changes are. This work builds on previous experiments evaluating cholinergic antagonists. Participants will complete two treatment arms. One of these will be with the drug, and the other will be with a placebo pill, so that the participants are unaware which session the actual drug has been received. Patients will complete a verbal serial recall and/or associative recognition task each of the two days. An anesthesiologist or patient nurse will administer either the drug or the placebo at a critical point which addresses both of the research questions. Researchers will compare the brain activity between the two treatment arms to determine what brain activity changes, and whether there is an additional behavioral effect on memory.
Interventions
- DRUG Placebo
- DRUG COBENFY KarXT (50/20 mg)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 50 participants |
| Start Date | 2026-10 |
| Est. Completion | 2031-10 |
| Phase | Early Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07228338
The ClinicalTrials.gov registry entry for NCT07228338 describes a study currently listed as not yet recruiting, categorized as Early Phase 1. The registered enrollment target is 50 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Texas Southwestern Medical Center, which has 837 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT07228338 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07228338 about?
NCT07228338 is a clinical study titled "Cholinergic Enhancement of Theta". The goal of this study is to learn about the effects of Cobenfy KarXT (xanomeline and trospium chloride) on episodic memory processing, including specific effects on areas of the brain involved in memory and changes it may have on brain activity. The investigators will do this by testing epileptic p...
What is the current status of trial NCT07228338?
This trial is currently not yet recruiting. It is a Early Phase 1 study. The enrollment target is 50 participants. The study started on 2026-10. Estimated completion is 2031-10.
What interventions are being tested in trial NCT07228338?
The interventions under investigation include: Placebo (DRUG), COBENFY KarXT (50/20 mg) (DRUG).
Who is sponsoring clinical trial NCT07228338?
This trial is sponsored by University of Texas Southwestern Medical Center, which has 837 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.